Mylan Launches MPA Injectable Suspension for Prevention of Pregnancy in the US

Shots:

• Generic launch of Pfizer’s Depo-Provera, Medroxyprogesterone Acetate (MPV) IV 150mg, is a Single-Dose Vial, which is in response to the FDA’s ANDA approval for the drug
• The launch will support the birth control rate in the US, with safety concerns of not using it more than 2 years as can lead to lose of bone mineral density
• According to IQVIA, Mylan has 179 ANDAs having pending FDA approval with ~$89.3B annual brand sales and in 31 July, 2018 MPA’s sales in the US was ~$181M

Click here to read full press release/ article | Ref: Mylan | Image: WVNews